Predicting outcomes after 177Lu-PSMA therapy in castration-resistant prostate cancer

The Lancet Oncology

Volume 22, Issue 10, October 2021, Page e425

There are more references available in the full text version of this article.

Proposal for an anti-TNF-exit strategy based on trough serum level
Biologicals, Volume 47, 2017, pp. 81-85
Ulf Helwig, …, Stefan Schreiber
WHO COVID-19 therapeutic guidelines – Authors' reply
The Lancet, Volume 398, Issue 10295, 2021, p. 118
Nicholas J White, …, Philippe J Guerin
Multicriteria optimization: Site-specific class solutions for VMAT plans
Medical Dosimetry, Volume 45, Issue 1, 2020, pp. 7-13
Mariana Guerrero, …, Shifeng Chen
Dying with cardiovascular disease, not of it
Trends in Cardiovascular Medicine, Volume 25, Issue 5, 2015, pp. 443-444
Samuel Wann
Predictors of Prostate-specific Membrane Antigen (PSMA/FOLH1) Expression in a Genomic Database
Urology, Volume 144, 2020, pp. 117-122
Clinton D. Bahler, …, Michael O. Koch
Expanding role of biomarkers in characterising hyperinflammatory syndromes
The Lancet Rheumatology, Volume 3, Issue 10, 2021, pp. e684-e685
Joseph M Rocco, Irini Sereti